VivoSeq
Psychiatry

Alcohol Use Disorder (AUD)

5

Pipeline Programs↗

12

Active Trials↗

5

Companies Involved↗

Alcohol Use Disorder (AUD) is an early-stage landscape with 5 programs across 5 companies. The most active players are Eli Lilly, Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Azurity Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

25/100

Mech. Concentration

25/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

2 programs

Phase 2C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 2A

Azurity Pharmaceuticals

1 program

Phase 2Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

PreclinicalA

Adial Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

4 of 5 classified programs — the dominant modality here.

20%ALL OTHERSPeptide120%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 83% of 6 pipeline programs.

Analysis

Trial Status

17

clinical trials

Recruiting8 · 47%
Completed5 · 29%
Not yet recruiting3 · 18%
Active, not recruiting1 · 6%

Clinical Trials

Trial Activity

17 trials

Guanfacine for Alcohol Use Disorder (AUD)
Recruiting·IIndiana University·Phase 2·NCT06629259·200 enrolled
The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)
Recruiting·YYale University·Phase 1·NCT06070649·63 enrolled
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
Recruiting·—·Phase 2·NCT04135846·184 enrolled
Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms
Recruiting·National Institute on Alcohol Abuse and Alcoholism (NIAAA)·Phase 1/2·NCT06484075·180 enrolled
Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)
Recruiting·—·Phase 2·NCT06853912·40 enrolled
Tirzepatide for the Treatment of Alcohol Use Disorder: A Pilot Randomized Controlled Trial
Recruiting·BBrigham and Women's Hospital·Phase 2·NCT06727331·20 enrolled
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
Recruiting·WWashington State University·Phase 2·NCT05181891·205 enrolled
A Double-masked, Randomized, Phase II Study to Compare the Effectiveness of 20mg Oral Suvorexant (SUV) Versus Placebo (1:1) in Participants With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)
Recruiting·PPharmacotherapies for Alcohol and Substance Use Disorders Alliance·Phase 2·NCT06679062·76 enrolled
Zonisamide for the Treatment of Alcohol Use Disorder in the Addiction Neuroclinical Assessment Framework
Active, not recruiting·WWashington State University·Phase 2·NCT05134857·205 enrolled
A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects
Not yet recruiting·CClearmind Medicine Inc.·Phase 1/2·NCT05913752·84 enrolled
Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)
Not yet recruiting·YYale University·Phase 1·NCT07223983·10 enrolled
Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving
Not yet recruiting·JJohns Hopkins University·Preclinical·NCT07148843·105 enrolled
Pilot Human Lab Study of Lacosamide in Alcohol Use Disorder (AUD)
Completed·UUniversity of California, San Francisco·Phase 2·NCT03897348·4 enrolled
Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)
Completed·UUniversity of Colorado, Denver·Phase 2·NCT05892432·50 enrolled
Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter Polymorphisms
Completed·AAdial Pharmaceuticals·Phase 3·NCT04101227·302 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)